Beigene, Ltd. (NASDAQ:ONC) Given Consensus Recommendation of "Buy" by Brokerages

Beigene, Ltd. (NASDAQ:ONC - Get Free Report) has received an average rating of "Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $319.00.

ONC has been the topic of a number of research reports. Macquarie boosted their target price on shares of Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Sanford C. Bernstein set a $259.00 target price on Beigene in a research report on Thursday, March 13th. Wall Street Zen raised Beigene from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and upped their price target for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Finally, TD Securities reiterated a "buy" rating and set a $334.00 price objective on shares of Beigene in a research report on Thursday, April 24th.

Insider Buying and Selling

In related news, insider Titus B. Ball sold 134 shares of Beigene stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $258.36, for a total value of $34,620.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Chan Henry Lee sold 700 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $256.11, for a total value of $179,277.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 228,258 shares of company stock worth $58,317,119. Corporate insiders own 6.62% of the company's stock.

Beigene Stock Performance

Shares of NASDAQ:ONC traded down $6.90 during trading on Friday, reaching $269.63. The company had a trading volume of 391,727 shares, compared to its average volume of 451,056. Beigene has a twelve month low of $141.31 and a twelve month high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The firm has a market cap of $31.92 billion, a price-to-earnings ratio of -32.72, a PEG ratio of 7.73 and a beta of 0.30. The business's fifty day moving average is $240.18.

Beigene (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. Equities analysts predict that Beigene will post -5.82 earnings per share for the current fiscal year.

About Beigene

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.